These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 12690546

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial.
    Sanz MA, López J, Lahuerta JJ, Rovira M, Batlle M, Pérez C, Vázquez L, Julià A, Palau J, Gutiérrez M, Capote FJ, Ramos F, Benlloch L, Larrea L, Jarque I, Spanish PETHEMA Group.
    J Antimicrob Chemother; 2002 Jul; 50(1):79-88. PubMed ID: 12096010
    [Abstract] [Full Text] [Related]

  • 5. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
    Aksoylar S, Cetingül N, Kantar M, Karapinar D, Kavakli K, Kansoy S.
    Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
    Sanz MA, Bermúdez A, Rovira M, Besalduch J, Pascual MJ, Nocea G, Sanz-Rodríguez C, COSTINE Study Group.
    Curr Med Res Opin; 2005 May; 21(5):645-55. PubMed ID: 15969864
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia.
    Rossini F, Terruzzi E, Verga L, Larocca A, Marinoni S, Miccolis I, Giltri G, Isella M, Parma M, Pogliani EM.
    Support Care Cancer; 2005 Jun; 13(6):387-92. PubMed ID: 15599778
    [Abstract] [Full Text] [Related]

  • 14. Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
    Hamidah A, Rizal AM, Nordiah AJ, Jamal R.
    Singapore Med J; 2008 Jan; 49(1):26-30. PubMed ID: 18204765
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A randomized monocentric trial in febrile neutropenic patients: ceftriaxone and gentamicin vs cefepime and gentamicin.
    Cornely OA, Bethe U, Seifert H, Breuer K, Schütt-Gerowitt H, Salzberger B, Schrappe M, Fätkenheuer G.
    Ann Hematol; 2002 Jan; 81(1):37-43. PubMed ID: 11807634
    [Abstract] [Full Text] [Related]

  • 18. A randomized prospective multicentre trial of cefpirome versus piperacillin-tazobactam in febrile neutropenia.
    Bauduer F, Cousin T, Boulat O, Rigal-Huguet F, Molina L, Fegueux N, Jourdan E, Boiron JM, Reiffers J, BGMT Collaborative Group.
    Leuk Lymphoma; 2001 Jul; 42(3):379-86. PubMed ID: 11699402
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.